NASDAQ$PETS
PetMed Express · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
PetMed Express reported a decrease in sales and net income for the first quarter of fiscal year 2023, while making strategic investments in infrastructure and partnerships.
PetMed Express reported a decrease in sales to $70.2 million compared to $79.3 million in the same period last year, impacted by a slow start to the flea and tick season. Net income also decreased to $2.8 million, or $0.14 diluted earnings per share, compared to $4.4 million, or $0.22 diluted earnings per share, in the prior year. Despite the sales decline, the company saw a rebound in sales from its returning customer base later in the quarter and is focusing on long-term growth through investments in infrastructure, partnerships, and expansion into the broader wellness market.
- First quarter sales were $70.2 million, down from $79.3 million in the same period last year, due to a slow start to flea and tick season.
- Net income decreased to $2.8 million, or $0.14 diluted earnings per share, compared to $4.4 million, or $0.22 diluted earnings per share, in the prior year.
- The company is investing in infrastructure, including processes, systems, and people, to grow long-term shareholder value.
- PetMeds is expanding from a primarily existing customer-focused business to include a focus on generating new customers.
Headline financials
Revenue & EPS history
PetMed Express · Revenue · Quarterly
$70.2M
Forward guidance
PetMeds is focused on improvement in new customer growth, continued migration to a recurring subscription model, active deployment of capital, full rollout of pet telemedicine capability, and expansion of product catalog and services.
Tailwinds
- Expanding and accelerating new customer acquisition efforts.
- Continuing migration of business to a recurring subscription model.
- Leveraging capital to accelerate transformation through investments, partnerships, and acquisitions.
- Executing on the deployment and expansion of integrations and partnership with Vetster.
- Expanding product catalog and services, including a wider product assortment and more health and wellness services.
Headwinds
- It takes time to transform a company, especially in a highly competitive market and in an uncertain economic environment.
- The company saw a slow start to flea and tick season due to seasonally colder temperatures, which continued into the early part of the most recent quarter.
- First quarter sales were down 11.5% year-over-year.
- The company hasn’t produced the results in net new customer growth.
- General and administrative expenses increased on a year-over-year basis.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-0.0%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
27 / 65 earnings
Positive
+40.8%
Q2 2020
Best reaction
-26.4%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -16.4% | -21.1% | — | |
| Q3 2026 | -3.6% | -8.7% | -15.5% | |
| Q4 2025 | +0.0% | -4.9% | -6.6% | |
| Q2 2026 | -1.4% | -2.7% | -8.2% | |
| Q1 2026 | -1.1% | -1.4% | -6.9% | |
| Q3 2025 | -14.8% | -20.1% | -22.7% | |
| Q2 2025 | +34.5% | +27.2% | +35.0% | |
| Q1 2025 | -11.0% | -13.0% | -4.5% | |
| Q4 2024 | -0.7% | -1.7% | -7.4% | |
| Q3 2024 | +0.2% | -1.2% | +8.9% | |
| Q2 2024 | -26.4% | -23.0% | -22.6% | |
| Q1 2024 | -2.8% | -6.4% | -20.0% | |
| Q4 2023 | +6.7% | +1.0% | -6.6% | |
| Q3 2023 | -11.1% | -13.3% | -19.6% | |
| Q2 2023 | -10.5% | -4.7% | -15.5% | |
| Q1 2023 | +4.3% | +4.2% | +0.9% | |
| Q4 2022 | +6.9% | +2.0% | +3.0% | |
| Q3 2022 | +7.2% | +7.7% | +3.4% | |
| Q2 2022 | +5.1% | +5.1% | +5.2% | |
| Q1 2022 | +7.1% | +13.0% | +3.2% | |
| Q4 2021 | +2.8% | +0.5% | +56.5% | |
| Q3 2021 | -14.3% | -11.1% | +3.2% | |
| Q2 2021 | -2.2% | -3.5% | -1.9% | |
| Q1 2021 | -16.0% | -23.8% | -17.4% | |
| Q4 2020 | +3.6% | -4.0% | -7.5% | |
| Q3 2020 | -11.0% | -11.2% | +4.0% | |
| Q2 2020 | +40.8% | +32.8% | +21.7% | |
| Q1 2020 | +2.5% | -1.5% | +5.1% | |
| Q4 2019 | -9.0% | -9.7% | -18.9% | |
| Q3 2019 | -6.2% | -3.4% | -3.1% | |
| Q2 2019 | +2.6% | +1.1% | -9.7% | |
| Q1 2019 | -13.0% | -11.8% | -6.4% | |
| Q4 2018 | -0.9% | +1.4% | +15.1% | |
| Q3 2018 | -4.8% | -10.2% | -12.0% | |
| Q2 2018 | +4.4% | -5.0% | +9.0% | |
| Q1 2018 | +18.6% | +19.3% | -10.7% | |
| Q4 2017 | +34.7% | +41.2% | +48.4% | |
| Q3 2017 | -5.1% | -5.4% | -3.6% | |
| Q2 2017 | -3.2% | -4.0% | +6.6% | |
| Q1 2017 | +6.0% | +5.8% | +3.3% | |
| Q4 2016 | +2.9% | — | — | |
| Q3 2016 | -4.8% | — | — | |
| Q2 2016 | +2.1% | — | — | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | +2.6% | — | — | |
| Q3 2015 | +14.3% | — | — | |
| Q2 2015 | -3.7% | — | — | |
| Q1 2015 | +5.0% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2014 | -12.0% | — | — | |
| Q2 2014 | -10.3% | — | — | |
| Q1 2014 | +12.7% | — | — | |
| Q4 2013 | -0.5% | — | — | |
| Q3 2013 | +7.0% | — | — | |
| Q2 2013 | +6.9% | — | — | |
| Q1 2013 | -16.3% | — | — | |
| Q4 2012 | -5.4% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2011 | -0.2% | — | — | |
| Q3 2012 | -0.2% | — | — | |
| Q2 2012 | -0.8% | — | — | |
| Q2 2011 | -0.8% | — | — | |
| Q1 2012 | -0.1% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2011 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro